First patient in Canada receives mRNA-based bladder cancer treatment in clinical trial at the MUHC
The investigational therapy combines mRNA technology with immunotherapy to train the immune system to target cancer cells after surgery
SOURCE: Research Institute of the McGill University Health Centre
The Research Institute of the McGill University Health Centre (The Institute) has achieved a new milestone in precision cancer medicine. Under the leadership of Dr. Ramy Saleh at the Centre for Innovative Medicine (CIM), a patient at the McGill University Health Centre (MUHC) is the first person in Canada to receive a new investigational therapy using mRNA technology to combat bladder cancer.
The therapy is being tested as part of a global randomized clinical trial evaluating an individualized mRNA-based approach in combination with immunotherapy. The trial targets bladder cancer, the fourth most commonly diagnosed cancer in Canadian men.
What makes this trial unique?
This trial represents a significant advancement in the application of mRNA technology beyond infectious disease prevention and into the realm of oncology. While mRNA-based vaccines—such as for COVID-19—deliver genetic instructions that prompt cells to produce a target protein and prompt an immune response, this therapy applies the same principle to cancer.
In this trial, the bladder cancer tumour is first surgically removed. Then, comprehensive molecular sequencing is conducted to identify mutations and tumour-specific neoantigens—proteins that are specific to the tumour and not found in the patient’s normal DNA. These findings are used to create a personalized mRNA therapy tailored to the patient’s tumour profile. Once administered, the treatment primes the immune system to recognize and attack any remaining cancer cells.
Leading in precision medicine
“For patients and families facing bladder cancer, access to cutting-edge treatment can make all the difference,” says Dr. Ramy Saleh, Medical Director for Oncology Clinical Trials at the CIM. “We’re proud that the first patient in Canada to receive this individualized mRNA therapy is being treated here. Every trial is a step forward - not just for science, but for the people we care for every day.”
This achievement supports The Institute’s 2030 Vision, which places precision medicine at the core of its mission. Through the CIM and its expanding leadership in mRNA research, immunotherapy, and next-generation treatments - including novel radiotherapeutics - The Institute is establishing itself as a centre of excellence for individualized, science-driven care in Quebec and across Canada.